In a murine model of type III OI, treatment with an anti-sclerostin antibody significantly improved BMD, tibial cortical thickness, ultimate load, and stiffness.256 Furthermore, an open-label phase 2 clinical trial evaluated the pharmacodynamics and safety of BPS804, an anti-sclerostin antibody, in adults with moderate OI. The gene discussed is SOST; the disease is osteogenesis imperfecta.